Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. That’s Bad for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Novo faces ‘Nokia risk’ as it fights Lilly’s homecourt advantage
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
This Is What Whales Are Betting On Novo Nordisk
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...
Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 — Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $115.65, down $0.83 or 0.71% --Would be lowest close since Feb. 2, 2024, when it closed at $113.70 --Currently down six consecutive days; ...
Texas attorney general sues insulin makers and pharmacy middlemen over high costs
Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly, Novo Nordisk and Sanofi.
verywellhealth3d
Why Is Ozempic So Expensive? Novo Nordisk Blames Prescription Drug Middlemen
"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...